Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
HPP737 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| HPP737 20mg | EXPERIMENTAL | Specification:10mg; Participants receive HPP737 20 mg orally once daily for 16 weeks. |
| Aprmilast 30mg Bid | ACTIVE_COMPARATOR | Participants receive Apremilast for 16 weeks. According to product label, 5-day dose titration is required: Day 1: 10 mg in the morning; Day 2: 10 mg in the morning and 10 mg in the evening; Day 3: 10 mg in the morning and 20 mg in the evening; Day 4: 20 mg in the morning and 20 mg in the evening; Day 5: 20 mg in the morning and 30 mg in the evening; Day 6 and thereafter: 30 mg twice daily (morning and evening, approximately 12 hours apart). |
| HPP737 10 mg | EXPERIMENTAL | Specification: 10 mg Dosage and Administration: Two capsules (one with 10 mg HPP737 and one with 10 mg placebo) are administered orally once daily for a total duration of 52 weeks. |
| HPP737 20 mg | EXPERIMENTAL | Specification: 10 mg Dosage and Administration: Two capsules (two with 10 mg HPP737) are administered orally once daily for a total duration of 52 weeks. |
| Placebo (cross over to HPP737 20mg at Week 17) | PLACEBO_COMPARATOR | Specification: 10 mg Administration and dosage: Two capsules (two with 10 mg placebo) are administered orally once daily for a total duration of 16 weeks. Then patients will be crossed over to receive HPP737 20 mg once daily starting at Week 17 and continuing through Week 52. |
| Name | Type | Description |
|---|---|---|
| HPP737 | DRUG | HPP737 capsules for oral administration. |
| Placebo matching HPP737 | DRUG | Placebo capsules matching HPP737 for oral administration. |
| Apremilast | DRUG | Apremilast tablets for oral administration. |
| Placebo matching Apremilast | DRUG | Placebo tablets matching Apremilast for oral administration. |
Inclusion Criteria: * Subjects must voluntarily sign the informed consent form prior to the initiation of any trial-related procedures, be able to communicate effectively with the investigators, and understand and comply with the requirements of this trial; * Age at the time of signing the informed...
HPP737 is an investigational small molecule being developed for the treatment of psoriasis, specifically moderate-to-severe plaque psoriasis in adult patients. It is currently in Phase 3 clinical development and has not been approved by regulatory authorities.
HPP737 is being developed by Genelux Corporation, a biopharmaceutical company listed on the stock exchange under the ticker symbol GNLX. The company is conducting clinical trials for this drug candidate in the dermatology therapeutic area.
HPP737 is in Phase 3 clinical development for the treatment of psoriasis. It is an investigational drug, meaning it has not yet received regulatory approval and is still undergoing clinical trials to evaluate its safety and efficacy in patients.
HPP737 has been studied in two completed Phase 3 clinical trials in China for plaque psoriasis. These trials, identified as NCT07712705 and NCT07712731, enrolled a total of 1,122 adult patients aged 18 years and older. Both trials were randomized, double-blind, and placebo-controlled.
HPP737 is a distinct investigational small molecule developed by Genelux Corporation. No alternative names for this drug have been reported in the clinical trial information available.